Nebenwirkungen · Alecensa
Alecensa 150 mg hard capsules · Abschnitt 4.8 · PDF-Seite 9
HOS-135886 · Präparat HOS-097784
Table 3 ADRs reported in Alecensa clinical trials (BO40336, BO28984, NP28761, NP28673; N = 533) System organ class Alecensa ADRs (MedDRA) N = 533 Frequency category Frequency category (all grades) (grades 3-4) Blood and lymphatic system disorders Anaemia1) Very common Common 2) Haemolytic anaemia Common -* Nervous system disorders Dysgeusia3) Common Uncommon Eye disorders Vision disorders4) Common -* Cardiac disorders Bradycardia5) Very common -* Respiratory, thoracic and mediastinal disorders Interstitial lung disease / Common Uncommon pneumonitis Gastrointestinal disorders Diarrhoea Very common Common Vomiting Very common Uncommon Constipation Very common Uncommon Nausea Very common Uncommon Stomatitis6) Common Uncommon Hepatobiliary disorders Increased AST Very common Common Increased ALT Very common Common Increased bilirubin7) Very common Common Increased alkaline Very Common Uncommon phosphatase Drug-induced liver injury8) Uncommon Uncommon Skin and subcutaneous tissue disorders Rash9) Very common Common Photosensitivity Common Uncommon
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-31T12:39:00Z · SHA-256 c661360f23ce41296ba8174d095b12ebdf58fe24b9cabe9f90341e85e092a395 · Passage f0f67f2e0c005d9be6c73789209461b91fb1602ce7c4bdde2b3c09debc7354ce · Zeichen 1641–3991 im Abschnitt